The key COVID-19 findings in hepatology, distilled into a clear, readable brief. The evidence is here whenever you want to go deeper.
INSIDE THIS MONITOR
37cited sources
4available findings
Study findings updated
AI-assisted evidence summary. For general information. These findings are not individual medical advice or a clinician endorsement.
THE SHORT VERSION
What’s worth knowing.
The key findings, what they mean, and the context that matters.
THE HEADLINE TAKEAWAY25-30%
Liver enzyme abnormalities occurred in 25-30% of hospitalized COVID-19 patients
The estimate was 25-30% among hospitalized COVID-19 patients, rising to 45-52% in severe cases.
This came from a systematic review with meta-analysis of liver manifestations in COVID-19; definitions and the observation timeframe are not available in this summary.
See the evidence
of hospitalized COVID-19 patients develop liver enzyme abnormalities
25-30%
Kulkarni AV, Kumar P, Sharma M, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Alimentary Pharmacology & Therapeutics. 2020;52(4):584-599.
Study-specific findings. Different populations, treatments and follow-up periods can produce different results.
THE RESEARCH, AS IT ARRIVES
Latest studies.
The newest findings added to this collection. The learning from each, already distilled.
Study summaries are not available in this collection yet. The original evidence remains accessible in each monitor.
Dates show when findings were added here, not when papers were published. Study populations and comparisons differ.
WHEN YOU WANT TO GO DEEPERSee all 4 findingsOriginal results, comparisons and study details.
3 of 3 source groupsFindings stay together with their study.
SOURCE 012 findings
Kulkarni AV, Kumar P, Sharma M, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Alimentary Pharmacology & Therapeutics. 2020;52(4):584-599.
Pan L, Huang P, Xie X, et al. Metabolic-associated fatty liver disease increases the severity of COVID-19: A meta-analysis. Hepatology International. 2021;15:1-10.
Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. Journal of Hepatology. 2021;74(3):567-577.
Browse the 37 original sourcesThe complete bibliography behind this monitor.
[1]
Kulkarni AV, Kumar P, Sharma M, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Alimentary Pharmacology & Therapeutics. 2020;52(4):584-599.
Sultan S, Altayar O, Siddique SM, et al. AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19. Gastroenterology. 2020;159(1):320-334.e27.
Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19. Lancet Gastroenterology & Hepatology. 2020;5(7):667-678.
Singh S, Khan A. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease. Gastroenterology. 2020;159(2):768-771.e3.
Pan L, Huang P, Xie X, et al. Metabolic-associated fatty liver disease increases the severity of COVID-19: A meta-analysis. Hepatology International. 2021;15:1-10.
Marjot T, Moon AM, Cook JA, et al. Outcomes following SARS-CoV-2 infection in patients with chronic liver disease: An international registry study. Journal of Hepatology. 2021;74(3):567-577.
Iavarone M, D'Ambrosio R, Soria A, et al. High rates of 30-day mortality in patients with cirrhosis and COVID-19. Journal of Hepatology. 2020;73(5):1063-1071.
Kim D, Adeniji N, Latt N, et al. Predictors of Outcomes of COVID-19 in Patients With Chronic Liver Disease. Clinical Gastroenterology and Hepatology. 2021;19(7):1469-1479.e19.
Zhou YJ, Zheng KI, Wang XB, et al. Metabolic-associated fatty liver disease is associated with severity of COVID-19. Liver International. 2020;40(9):2160-2163.
Roca-Fernandez A, Wamber-Thompson A, Sherwood S, et al. Liver Disease in Patients with COVID-19 in the UK Biobank. Lancet Gastroenterology & Hepatology. 2022;7(10):920-930.
Original source link unavailable
[12]
Beigel JH, Tomashek KM, Dodd LE, et al. Remdesivir for the Treatment of Covid-19 - Final Report. New England Journal of Medicine. 2020;383(19):1813-1826.
Hammond J, Leister-Tebbe H, Gardner A, et al. Oral Nirmatrelvir for High-Risk, Nonhospitalized Adults with Covid-19. New England Journal of Medicine. 2022;386(15):1397-1408.
Zuo T, Zhang F, Lui GCY, et al. Alterations in Gut Microbiota of Patients With COVID-19 During Hospitalization. Gastroenterology. 2020;159(3):944-955.e8.
La Mura V, Artru F, Leiria N, et al. COVID-19 in patients with cirrhosis: Impact on portal hypertension complications. Hepatology. 2021;74(3):1234-1244.
Original source link unavailable
[28]
Gupta S, Ahuja N, Mohanty S, et al. Splanchnic vein thrombosis in COVID-19: Clinical presentation and outcomes. Clinical Gastroenterology and Hepatology. 2021;19(11):2398-2400.
Original source link unavailable
[29]
Bakasis AD, Bitzogli K, Mouziouras D, et al. Efficacy and Safety of COVID-19 Vaccines in Patients with Liver Disease. Vaccines. 2022;10(4):564.
Rabinowich L, Gruber R, Benmati N, et al. Low immunogenicity to SARS-CoV-2 vaccination among liver transplant recipients. Journal of Hepatology. 2021;75(2):435-438.
European Association for the Study of the Liver (EASL). EASL position paper on the use of COVID-19 vaccines in patients with chronic liver diseases. Journal of Hepatology. 2021;74(4):944-951.
American Association for the Study of Liver Diseases (AASLD). Clinical insights for hepatology and liver transplant providers during the COVID-19 pandemic. 2020-2023.
Original source link unavailable
[33]
Marjot T, Webb GJ, Barritt AS 4th, et al. COVID-19 and liver disease: mechanistic and clinical perspectives. Nature Reviews Gastroenterology & Hepatology. 2021;18(5):348-364.
SECURE-Cirrhosis (Surveillance Epidemiology of Coronavirus Under Research Exclusion). International registry reporting outcomes in patients with cirrhosis and COVID-19. 2020-2024.
This is an AI-assisted evidence summary, not a clinician endorsement. Read each original paper for its complete methods, population and limitations. Different studies can ask different questions and report different kinds of results.
Dates marked “added” describe when a finding entered this monitor, not when the study was published or clinically reviewed. Personal health and treatment decisions belong in a conversation with a qualified clinician.